Category: Prematurity
Poster Session II
Although most pregnant persons with nausea and vomiting of pregnancy (NVP) have symptoms that improve after the first trimester, approximately 20% experience NVP later in gestation. Little is known about pregnancy outcomes among these individuals. We aimed to investigate pregnancy outcomes among those with NVP after the first trimester.
Study Design:
This is a secondary analysis of 9117 nulliparas from the NuMoM2b cohort who underwent NVP assessment with the Pregnancy-Unique Quantification of Emesis (PUQE) scale at three study visits; “V1” at 12.5±2.7 weeks, “V2” at 19.4±2.5 weeks, and “V3” at 28.0±3.2 weeks. Scores ranged 3-15 and were classified as having no NVP symptoms (PUQE score=3), mild (4-6) or moderate/severe (≥ 7) NVP at each visit. Chi-square analyses were used to compare the rate of adverse pregnancy outcomes (APO); small for gestational age, gestational hypertension, stillbirth, gestational diabetes, preterm birth (PTB) < 34 weeks, PTB < 37 weeks, across NVP categories at each study visit. Separate logistic regression models were used to estimate the association between degree of NVP at each visit and the odds of PTB < 37 weeks – adjusted for covariates (age, body mass index, race/ethnicity, smoking, gestational hypertension, depression). A separate sensitivity analysis was performed with additional adjustment for rate of gestational weight gain (GWG) per week.
Results:
Degree of NVP at V1 and V3 was not associated with APO. There was a higher rate of PTB < 37 weeks in those with mild (10.1%) and moderate/severe NVP (13.3% ) versus having no NVP (8.2%) in V2 (χ2=13.8, p=0.001) (Table 1). On adjusted analysis, there was a marginally higher odds of PTB < 37 weeks among those with mild NVP at V2 (OR 1.21, 95% CI 1.00 to 1.47, p=0.050) and significantly higher odds with moderate/severe NVP at V2 (OR 1.60, 95% CI 1.09 to 2.36, p=0.017) versus having no NVP. This relationship was strengthened after adding GWG as a covariate (OR 1.85, 95% CI: 1.20 to 2.86, p=0.005).
Conclusion:
Moderate/severe NVP in mid-gestation may be associated with a higher risk of PTB.
Gina F. Milone, MD (she/her/hers)
Fellow Physician
University of California, Irvine
Long Beach, California, United States
Karen L Lindsay, PhD
Assistant Professor
Department of Pediatrics, University of California, Irvine
Irvine, California, United States
Brian M. Mercer, MD
Department Chair of Obstetrics & Gynecology
Case Western Reserve University and The MetroHealth System
Cleveland, Ohio, United States
George R. Saade, MD
Professor & Chief of Obstetrics & Maternal-Fetal Medicine
University of Texas Medical Branch
Galveston, Texas, United States
Bob M. Silver, MD
Chair OB/GYN
Univ. of Utah School of Medicine
Salt Lake City, Utah, United States
David M. Haas, MD, MSCR
Attending Physician
Indiana University Health
Carmel, Indiana, United States
Hyagriv Simhan, MD,MSCR
Magee-Womens Hospital, University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Samuel Parry, MD
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Uma M. Reddy, MD,MPH
Professor and Vice Chair of Research, Department of Obstetrics and Gynecology
Columbia University
New York, New York, United States
Judith H. Chung, MD, PhD
Professor of Clinical Obstetrics and Gynecology
UC Irvine Health
Orange, California, United States